Latest On Ipsen S.A (IPSEY):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-06-02 06:02 EST | Dividend | A dividend of $0.32 has been announced on May 19, 2023. It will be paid Jun 27, 2023 with an ex-dividend date of Jun 2, 2023. | Neutral |  |
| 2023-04-24 13:21 EST | News | Ipsen appoints new chief medical officer | N/A | |
| 2023-04-19 18:14 EST | News | Ipsen: Positive On Bylvay But Uncertain About 2028/2029 Expiries | N/A | |
| 2022-08-16 18:40 EST | News | Epizyme Acquisition By Ipsen: CVR Value | N/A | |
| 2022-08-16 18:39 EST | News | Hutchmed begins dosing in mid-stage study of tazemetostat in blood cancer subtype | N/A | |
| 2022-08-16 18:38 EST | News | Epizyme GAAP EPS of -$0.21, revenue of $27.5M | N/A | |
| 2022-07-28 03:34 EST | News | Ipsen S.A. Non-GAAP EPS of €4.74, revenue of €1.43B | N/A | |
| 2022-06-01 08:38 EST | News | Ipsen launches share buyback for employee free share-allocation plan | N/A | |
| 2022-05-31 06:02 EST | Dividend | A dividend of $0.32 has been announced on May 20, 2022. It will be paid Jun 9, 2022 with an ex-dividend date of May 31, 2022. | Neutral | |
| 2022-01-24 14:27 EST | News | Health Canada approves Ipsen’s Sohonos for fibrodysplasia ossificans progressiva | N/A | |
| 2021-10-19 02:31 EST | News | Ipsen and Accent ink potential $446M collaboration agreement for METTL3 leukemia program | N/A | |
| 2021-08-14 02:05 EST | News | Ipsen withdraws palovarotene NDA following FDA discussions | N/A | |
| 2021-08-02 09:11 EST | News | Exicure soars 38% on collaboration with Ipsen targeting rare neurodegenerative disorders (updated) | N/A | |
| 2021-07-27 21:10 EST | News | Ipsen and BAKX Therapeutics ink BKX-001 worldwide-collaboration agreement | N/A | |
| 2021-07-22 14:06 EST | News | FDA accepts Ipsen's genetic disorder treatment NDA for review | N/A | |
| 2021-07-22 14:06 EST | News | Ipsen launches Employee Shareholding plan | N/A | |
| 2021-07-22 14:06 EST | News | Ipsen initiates a buy-back program to cover its employee shareholding plans | N/A | |
| 2021-07-22 14:05 EST | News | Exelixis drops 6% on disappointing cabozantinib combo data in late-stage liver cancer study | N/A | |
| 2021-07-22 14:04 EST | News | Ipsen buys exclusive rights to IRLAB's Parkinson’s disease treatment in $363M deal | N/A | |
| 2021-05-28 06:08 EST | Dividend | A dividend of $0.31 has been announced on Nov 30, -0001. It will be paid Jun 9, 2021 with an ex-dividend date of May 28, 2021. | Neutral | |
| 2021-04-01 08:52 EST | News | Exelixis’ partner Ipsen win EU approval for Cabometyx combo in kidney cancer | N/A | |
| 2021-02-17 01:36 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-11 18:06 EST | News | Ipsen S.A. reports FY results | N/A | |
| 2021-01-15 19:22 EST | News | Ipsen's Dysport shows long duration of response in management of cervical dystonia and spasticity | N/A | |
| 2020-12-03 15:18 EST | News | Merrimack Pharma jumps 42% on bullish timeline for potential Onivyde milestone payment | N/A | |
| 2020-11-26 23:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 02:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-27 07:47 EST | News | Crinetics Pharma lead drug successful in mid-stage acromegaly study | N/A | |
| 2020-09-26 15:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 07:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-16 07:32 EST | News | IPSEN buys back 5,280 shares | N/A | |
| 2020-09-09 07:11 EST | News | IPSEN buys back 23,647 shares | N/A | |
| 2020-09-05 20:30 EST | News | Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop | N/A | |
| 2020-09-04 16:10 EST | News | Crinetics Pharma to advance ACTH antagonist candidate into the clinic | N/A | |
| 2020-08-26 02:27 EST | News | IPSEN buys back ~11.6k shares | N/A | |
| 2020-08-14 11:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 15:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-01 02:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 19:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 07:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 23:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 17:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 15:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 19:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-14 01:22 EST | News | Ipsen +6.1% on share repurchase | N/A | |
| 2020-07-09 11:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-03 00:28 EST | News | Ipsen teams up for cabozantinib combo study in lung and prostate cancer | N/A | |
| 2020-07-01 22:15 EST | News | Ipsen irinotecan regimen shows positive action in first-line pancreatic cancer | N/A | |
| 2020-07-01 19:03 EST | Financials | Company financials have been released. | Neutral | |
About Ipsen S.A (IPSEY):
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company offers drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. Further, the company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; Etiasa for inflammatory bowel diseases. Additionally, it offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, and Mucodyne. The company has collaboration agreements with Arix Bioscience plc; The University of Texas MD Anderson Cancer Center; and Exelixis. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.
General
- Name Ipsen S.A
- Symbol IPSEY
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 5,700
- Fiscal Year EndDecember
- Web URLhttp://www.ipsen.com
Valuation
- Trailing PE 16.5
- Forward PE 9.39
- Price/Sales (Trailing 12 Mt.) 2.14
- Price/Book (Most Recent Quarter) 2.69
- Enterprise Value Revenue 2.15
- Enterprise Value EBITDA 7.3
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 20%
- Return on Assets 10%
- Return on Equity 28%
- Earnings Per Share $1.20
- Revenue Per Share $0
- Gross Profit 2.2 billion
- Quarterly Earnings Growth -1.5%
Highlights
- Market Capitalization 6.58 billion
- Book Value Per Share $5.87
Share Statistics
- Shares Outstanding 330.97 million
- Shares Float 139.28 million
- % Held by Insiders <1%
Technicals
- Beta 0.91
- 52 Week High $27.58
- 52 Week Low $11.41
- 50 Day Moving Average 21.4
- 200 Day Moving Average 22.88
Dividends
- Forward Annual Dividend Rate $0.28
- Forward Annual Dividend Yield 1.42%
- Payout Ratio 4%
- Dividend Date 2020-06-12
- ExDividend Date 2020-06-03
- Dividend Per Share $1.17
- Dividend Yield 0%
Ipsen S.A (IPSEY) Dividend Calendar:
IPSEY's last dividend payment was made to shareholders on June 12, 2020.
Ipsen S.A pays out 4% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Ipsen S.A (IPSEY) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | $2.37 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $N/A | $2.28 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | $1.49 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $699.95 million | $1.46 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $699.95 million | -$1.83 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $646.45 million | -$1.78 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $646.45 million | $1.47 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $611.65 million | $1.45 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $611.65 million | $1.30 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $426.63 million | $1.32 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $435.65 million | $1.39 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $42.11 million | $1.47 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $38.29 million | $1.05 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $484.85 million | $1.03 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $484.85 million | $0.86 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $432.25 million | $0.80 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $432.25 million | $0.59 | $0.00 | |
| 2016-06-30 | 2016-09-30 | $0.63 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | $0.90 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | $0.92 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | $0.65 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | $0.67 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | $0.61 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | $0.58 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | $0.36 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | $0.38 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | $0.87 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.87 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.43 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.42 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $0.70 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $0.69 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | $0.75 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.80 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | -$0.15 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | -$0.15 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.79 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $0.77 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.16 | $0.00 |
Ipsen S.A (IPSEY) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 106.25 million |
| Income Before Tax | N/A | N/A | N/A | N/A | -159.6 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 264.95 million |
| Gross Profit | N/A | N/A | N/A | N/A | 574.4 million |
| Ebit | N/A | N/A | N/A | N/A | 168.1 million |
| Operating Income | N/A | N/A | N/A | N/A | 168.1 million |
| Income Tax Expense | -32.65 million | -32.65 million | 23.75 million | 23.75 million | -24.15 million |
| Total Revenue | N/A | N/A | N/A | N/A | 699.95 million |
| Cost of Revenue | N/A | N/A | N/A | N/A | 125.55 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -327.7 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | -135.45 million |
| Net Income Applicable to Common Shares | 163.05 million | 163.05 million | 110.95 million | 110.95 million | -135.4 million |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -5.3 million | -5.3 million | N/A |
| Change to Liabilities | -13.9 million | -13.9 million | 50.15 million | 50.15 million | -950000 |
| Total Cash Flow from Investing Activities | -33.15 million | -33.15 million | -83.25 million | -83.25 million | -495.4 million |
| Net Borrowings | -25.35 million | -25.35 million | -53.65 million | -53.65 million | 375.35 million |
| Total Cash Flow from Financial Activities | N/A | N/A | -56.25 million | -56.25 million | 331.25 million |
| Change to Operating Activities | -20.95 million | -20.95 million | 21.45 million | 21.45 million | -22.85 million |
| Change in Cash | N/A | N/A | 79 million | 79 million | -64.95 million |
| Total Cash from Operating Activities | 146.8 million | 146.8 million | 217.5 million | 217.5 million | 96.35 million |
| Depreciation | N/A | N/A | 42.05 million | 42.05 million | 38.55 million |
| Other Cash Flow from Investing Activities | -5.75 million | -5.75 million | 12.6 million | 12.6 million | -37.35 million |
| Change to Inventory | N/A | N/A | -7.1 million | -7.1 million | -5.7 million |
| Change to Account Receivables | N/A | N/A | 4.45 million | 4.45 million | -44.4 million |
| Other Cash Flow from Financing Activities | -2.65 million | -2.65 million | 4.2 million | 4.2 million | -950000 |
| Change to Net Income | 8.05 million | 8.05 million | 233 million | 233 million | 15.35 million |
| Capital Expenditures | N/A | N/A | 34.25 million | 34.25 million | 38 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 2.55 billion |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 1.75 billion |
| Other Current Liabilities | 715.1 million | 715.1 million | N/A | N/A | 329.6 million |
| Total Assets | N/A | N/A | N/A | N/A | 4.31 billion |
| Common Stock | 83.8 million | 83.8 million | 83.8 million | 83.8 million | 83.8 million |
| Other Current Assets | 113.7 million | 113.7 million | N/A | N/A | 132.1 million |
| Retained Earnings | 548 million | 548 million | 221.9 million | 221.9 million | -50.7 million |
| Other Liabilities | 982.4 million | 982.4 million | 243 million | 243 million | 246.7 million |
| Other Assets | 251.2 million | 251.2 million | 184.9 million | 184.9 million | 153.9 million |
| Cash | N/A | N/A | N/A | N/A | 353.3 million |
| Total Current Liabilities | 1.21 billion | 1.21 billion | N/A | N/A | 1.45 billion |
| Other Stockholder Equity | -59.6 million | -59.6 million | 24.3 million | 24.3 million | 61.8 million |
| Property, Plant & Equipment | 646.6 million | 646.6 million | 654.2 million | 654.2 million | 679.3 million |
| Total Current Assets | 1.58 billion | 1.58 billion | N/A | N/A | 1.35 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 111.4 million |
| Net Tangible Assets | 405.1 million | 405.1 million | -17.7 million | -17.7 million | -264.8 million |
| Short Term Investments | N/A | N/A | N/A | N/A | 59.3 million |
| Long Term Debt | N/A | N/A | N/A | N/A | 854.7 million |
| Inventory | 213.9 million | 213.9 million | N/A | N/A | 214 million |
| Accounts Payable | 495.2 million | 495.2 million | N/A | N/A | 508.5 million |
Ipsen S.A (IPSEY) Chart:
Ipsen S.A (IPSEY) News:
Below you will find a list of latest news for Ipsen S.A (IPSEY) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Ipsen S.A (IPSEY) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Ipsen S.A (IPSEY) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|